Idorsia Pharmaceuticals has obtained a senior secured term loan of up to CHF 250 million from Pharmakon Advisors, with the first tranche of CHF 150 million used to refinance existing debt maturing in 2027. This refinancing eliminates near-term debt maturities, strengthens Idorsia's balance sheet, and extends its cash runway into 2028. Additional loan tranches may be drawn to support growth initiatives, reflecting Pharmakon's confidence in Idorsia's business and future potential. The company aims to accelerate growth and unlock the value of its portfolio while maintaining financial discipline.
SpaceX is preparing for its IPO with a business model that blends rocket launches, satellite broadband via Starlink, and AI infrastructure, making it hard for investors to value. This mix means analysts must compare SpaceX to aerospace, telecom, and ...
Village Super Market, Inc. announced quarterly cash dividends of $0.25 per Class A share and $0.1625 per Class B share. These dividends will be paid on July 23, 2026, to shareholders recorded by July 2, 2026. The company operates 34 supermarkets unde...
Village Super Market, Inc. announced quarterly cash dividends of $0.25 per Class A share and $0.1625 per Class B share. These dividends will be paid on July 23, 2026, to shareholders recorded by July 2, 2026. The company operates 34 supermarkets acro...
G6 Hospitality has elevated Nikhil Heda to Country Head for the U.S. and expanded Anuj Ladha's role as National Head of Brand Performance to accelerate growth across economy, midscale, and upscale segments. These leadership changes support G6's strat...
Space stocks fell sharply after SpaceX began trading publicly under the ticker SPCX, with shares rising 25.77% but triggering profit-taking in other space companies. A short seller report from Fugazi Research criticized six space-related stocks, call...
